[1] Amin LI, et al. Kras mutant protein inhibitors. Patent WO2021121367A1.
[2] Li J, Shen L, Gu Y, et al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors[J]. 2024.
[3] Ma C, et al. Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment. J Med Chem. 2024 Aug 22;67(16):13534-13549. DOI:
10.1021/acs.jmedchem.4c00360[4] Fuerst M L. Glecirasib Induces Promising Efficacy in Patients With Advanced Lung Cancer[J]. 2024.